The AMR Action Fund is the world’s largest public-private partnership investing in the development of new antimicrobial therapeutics.
The AMR Action Fund enables breakthroughs in antimicrobials.
We invest in companies that are developing urgently needed therapeutics for priority pathogens and advocate for market reforms to change how society values these lifesaving drugs. Our aim is to help launch two to four new antimicrobials within the next decade and create a sustainable ecosystem of investment and innovation to take on one of the biggest global health challenges of our generation.
The Threat of AMR
Access and Appropriate
The AMR Action Fund is committed to ensuring that the novel antibiotics it invests in are used appropriately and are accessible to the patients who need them. The AMR Action Fund will leverage its investments and capabilities platform to ensure that portfolio companies meet these principles.
The AMR Action Fund will invest in the development of antibiotics that address unmet medical needs prioritized by WHO, CDC, and other leading health authorities. The overall guiding principles for any decisions and actions by the AMR Action Fund and its portfolio companies should be to advance medical science, contribute to slowing the emergence of resistance, and support appropriate patient access. In addition to these patient and population health benefits, AMR Action Fund investments into appropriate use and access are also a key part of creating a sustainable commercial foundation and enhancing future partnership opportunities for portfolio companies.
The AMR Action Fund recognizes the complex nature of expanding access to antibiotics globally, given the challenges of ensuring appropriate use and reducing the development of resistance. Similar to other therapeutic areas, the pharmaceutical industry has an important role in supporting appropriate use and access for the products it develops. Ensuring affordable access to new and existing antibiotics, particularly in low- and middle-income countries, will require new partnerships with governments, donors, international organizations, industry, and civil society. The AMR Action Fund will advocate for creating new mechanisms and strengthening existing partnerships to facilitate increased appropriate access to novel antibiotics in low- and middle-income countries. Portfolio companies will identify countries where commercialisation is regarded as unfeasible within a reasonable time horizon and therefore these new mechanisms and additional support will be needed to enable access and appropriate use of novel antibiotics. In addition, governments need to strengthen health care systems to support access and appropriate use, and create market conditions that enable a sustainable return on investment, recognizing the value of novel antibiotics addressing high unmet needs.
Through its investments and capability platform, which provides connection to a diverse set of expertise from both industry and non-industry partners, the AMR Action Fund will provide vital support to portfolio companies to ensure activities are aligned with Access and Appropriate Use principles. The AMR Action Fund will work with portfolio companies to build access and appropriate use into antibiotic development strategies, and support companies to develop and make public Access and Appropriate Use Plans when assets are in Phase III clinical trials. These plans will include the strategies to be adopted by portfolio companies to promote access and appropriate use, including how they will work with partners in low- and middle-income countries, in line with guidance to be developed by the AMR Action Fund. The AMR Action Fund will monitor progress against these plans as part of its regular engagement with portfolio companies and will factor this into potential follow-on investments.